Company: MDCXW
Filing Date: 2025-05-05
Form Type: 253G2
Source: 0001062993-25-008440
Chunk: 26

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-05
Form: 253G2
Chunk 26
---
 payment for the partial year worked by Mr. Brennan up to the date notice is provided; (c) benefit plan contributions necessary to maintain the Mr. Brennan's participation during the two-month notice period in all benefit plans provided to the Mr. Brennan by the Company immediately before the termination; and (d) payment of amounts which may be due and remaining unpaid at the time of termination of employment such as Amended Brennan Base Salary, vacation pay and expenses properly accrued as of the termination date.

In the event of a Change of Control Transaction (as defined in the Amended Brennan Employment Agreement), any unvested options granted to Mr. Brennan shall immediately vest.

Liability Insurance of Directors and Officers

The Company has directors' and officers' liability insurance coverage for losses to the Company if the Company is required to reimburse directors and officers, where permitted, and for direct indemnity of directors and officers where corporate reimbursement is not permitted by law. The insurance protects the Company against liability (including costs), subject to standard policy exclusions, which may be incurred by directors and/or officers acting in such capacity for the Company. All directors and officers are covered by the policy and the amount of insurance applies to all directors and officers equally. This insurance provides a coverage limit of $10,000,000. For the year ended December 31, 2024, the Company paid $299,733 in liability insurance premium for our directors and our officers.

DIRECTOR COMPENSATION

Compensation of our directors generally consists of annual retainer fees and the Board and committee meeting fees, which are paid on a quarterly basis. There are no special arrangements between us and any director with respect to fees. Our directors are also entitled to participate in our equity incentive plan. Our executive officers who also act as directors do not receive any additional compensation for services rendered in their capacities as directors.

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth all compensation awarded to, or earned by, our non-executive directors for the year ended December 31, 2024.

| Director             |   Fees 
 earned 
 ($)(1) | Share-based 
 Awards      
 ($)         | Option-based 
       Awards 
          ($) | Non-         
 equity       
 incentive    
 plan         
 compensation 
 ($)          | Nonqualified 
 deferred     
 compensation 
 earnings     
 ($)          | All Other    
 Compensation 
 ($)          | Total Compensation 
                ($) |
| Dr. Larry Kaiser     | 60,000 | -           |       30,257 | -            | -